American company Svenox Pharmaceuticals LLC, which has its roots in the Czech Republic, bought patent applications for prospective antituberculotics from the Charles University.
Presented invention is related to a novel type of agents that can be used in treatment of tuberculosis. Svenox Pharmaceuticals LLC is committed to ensuring the necessary and cost-intensive development of the final drug and—in case of positive results—its subsequent application. Potential drug development should be conducted not only in the United States, but also in a number of countries within the European Union as well as in India or South Africa. CUIP conducted all negotiations with the investor, prepared the contract, and subsequently signed it on behalf of the Charles University. Therefore, Czech scientists are going to participate in fighting this insidious disease as well as have a share in revenues from this invention.